Nuclear medicine has moved from supporting imaging to the center of precision oncology. That was the message of the 2026 SNMMI (Society of Nuclear Medicine and Molecular Imaging) Annual Meeting in Los Angeles, where theranostics, radiopharmaceutical therapy, and cardiac PET/CT dominated the agenda — with one clear takeaway: the science is here, capital is moving in, and the bottleneck now is execution.
What once revolved around PET/CT scanners, tracers, and research has become a platform business. It is built on isotope production, radiopharmaceutical manufacturing, PET imaging, AI workflow, therapy delivery, oncology referrals, cardiac imaging, reimbursement, compliance, and scalable operations. It is an entire supply chain, not a single piece of equipment.
From imaging to treatment: theranostics at the core
Nuclear medicine is becoming central to oncology decision-making. PSMA, DOTATATE, amyloid, tau, cardiac PET, and targeted radionuclide therapies were presented as parts of a larger precision-medicine ecosystem. Sessions focused on the pressure points that will determine who wins: isotope availability, radiochemistry capacity, reimbursement, patient access, dosimetry, trained staff, nuclear-pharmacy support, AI workflow, and treatment-site readiness.
Theranostics — pairing a diagnostic tracer with a therapeutic agent that hit the same molecular target — is what places nuclear medicine in the same strategic category as immunotherapy and cell therapy. PSMA imaging, lutetium-177-based therapy, and actinium-225 ($^{225}$Ac) targeted alpha therapies were highlights. ASCO-focused programming connected oncology trial data directly to nuclear medicine, reinforcing that the field is now part of mainstream oncology strategy rather than mere imaging support.
The most mature example is prostate cancer: the same molecule that binds PSMA can be used to see the disease on PET and, coupled to a therapeutic radionuclide, to treat it. This “see-and-treat” with a single target is what makes theranostics so compelling — and so dependent on a reliable industrial chain. Each step, from cyclotron or generator to the patient’s bedside, has to work in concert.
Cardiac PET/CT: the new horizon
Cardiac imaging is undergoing its own platform shift. The market is moving from traditional SPECT toward cardiac PET/CT, where scan times drop from several hours to roughly 15 minutes while adding stronger quantification, workflow efficiency, and diagnostic confidence. For hospitals, cardiology groups, and outpatient imaging operators, that is a major development.
Cardiac PET/CT is not just a faster scan. It brings myocardial blood-flow quantification, better image quality, lower radiation exposure, and sharper assessment of coronary artery disease and microvascular disease — precisely the conditions SPECT struggles to characterize. The ability to measure coronary flow reserve changes the diagnostic conversation in patients who have symptoms but no obvious obstruction.
Adoption also reflects a workforce reality: PET cameras, rubidium generators, and flow-quantification software require teams comfortable with quantitative cardiac protocols. Where that expertise exists, throughput and diagnostic yield rise quickly; where it does not, expensive equipment can sit underused.
The real bottleneck is execution
Innovation gets attention, but reimbursement determines adoption. Across oncology, neuro-PET, and cardiac PET, uptake depends on clinical value, access, workflow, and payment clarity. Actinium-225 and lutetium-177 only reach the patient if isotope is available, a radiopharmacy can handle it, and a site is ready to deliver the dose with proper dosimetry.
That is where the bottleneck lives. Demand is building and capital is moving in, but isotope-production capacity, radiochemistry, and a trained workforce are not keeping pace. Solving this is less a scientific problem than a challenge of infrastructure, regulation, and staffing — exactly the themes that filled the hallways in Los Angeles. Execution, not discovery, will separate winners from also-rans.
Implications for practice
For imaging and radiation-oncology professionals, the message is to plan for a future where diagnosis and therapy move together. We have already covered how theranostics was named the image of the year at SNMMI 2026; what this analysis adds is the operational dimension — without an isotope supply chain and reimbursement, the clinical promise does not materialize.
The same PET that underpins theranostics also enables neuroimaging applications, such as tau PET for detecting encephalopathy, broadening the return on investment in a single technology base. For services weighing expansion, the reading is clear: investing in PET/CT today means investing in a platform, not a standalone exam.
In regions where PET/CT supply is still concentrated in large centers and domestic radiopharmaceutical production is limited, anticipating this curve is strategic. Building supply-chain and reimbursement pathways early is what will let smaller services participate in the theranostics era rather than referring every case elsewhere.
Outlook
SNMMI 2026 confirmed a transition: nuclear medicine as a pillar of oncology and, increasingly, of cardiology. The coming years will test whether infrastructure — isotopes, radiochemistry, dosimetry, and personnel — can keep up with clinical demand. Whoever solves the execution problem first will capture most of the value in this fast-expanding market.
Source: DOTmed — Theranostics, cardiac PET/CT and the next infrastructure buildout at SNMMI
